FIELD: food industry.
SUBSTANCE: use of a synthetic nutritional composition containing free form or salt form of choline to prevent, reduce the risk of, or mitigate a suboptimal de novo myelination trajectory in a subject fed with infant formula, wherein the subject is a human infant or a child, such as a human infant or child being fed with an infant formula, and where the specified composition contains choline in an amount of from 50 to 1,000 mg/100 g by dry weight of the composition, and where the human infant is an infant under the age of 12 months, and the child is a person aged from 1 to 18 years, preferably from 1 to 5 years; and where the de novo myelination trajectory is sub-optimal when the distance between any equivalent and/or identical infant trajectory measurement points and the trajectory achieved in exclusively breastfed infants during their first 3 months of life is greater than 50%. Synthetic nutritional composition containing free form or salt form of choline to prevent, reduce the risk of, or mitigate a suboptimal de novo myelination trajectory in a subject fed with an infant formula that also contains folic acid and vitamin B12, and a fatty acid compound other than phospholipid, including docosahexaenoic acid and/or arachidonic acid, and sphingomyelin, in which choline is present in the specified composition in an amount from 50 to 1,000 mg/100 g, while sphingomyelin is present in the specified composition in an amount from 300 mg/kg to 2.5 g/kg, while folic acid is present in the specified composition in an amount from 110 to 500 μg/100 g, and vitamin B12 is present in the specified composition in an amount from 5 to 10 μg/100 g, and iron is present in the specified composition in an amount from 5 to 40 mg/100 g, and the fatty acid compound containing DHA is present in the composition in an amount from 60 to 350 mg/100 g, and the fatty acid compound containing arachidonic acid (ARA) is present in the composition in an amount from 60 to 350 mg/100 g of the dry weight of the composition, in which the entire weight is indicated based on the dry weight of the composition. Wherein the said fatty acid compound is monoacylglycerol and/or diacylglycerol and/or triacylglycerol and is a composition selected from the group consisting of the following: infant formula, complementary milk, infant formula, which is intended to be added or diluted with breast milk and a food product intended for consumption by an infant and/or child, either alone or in combination with human breast milk, where the infant is an infant under 12 months of age and the child is a human between 1 and 18 years of age and preferably of 1 up to 5 years.
EFFECT: invention allows promoting stimulation, support or optimization of primary myelination.
10 cl, 49 dwg, 18 tbl, 7 ex
